Trimodality therapy for Pancoast tumors: T4 is not a contraindication to radical surgery

Ryuichi Waseda, Thomas Klikovits, Mir Alireza Hoda, Konrad Hoetzenecker, Pietro Bertoglio, Karin Dieckmann, Sabine Zöchbauer-Müller, Robert Pirker, Helmut Prosch, B. Döme, Walter Klepetko

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: This study aims to evaluate the impact of T stage and extended surgery on the outcome of patients with Pancoast tumors after induction chemoradiation therapy. Methods: Forty-six consecutive patients who underwent chemoradiation therapy (platin-based, 45-66 Gy) followed by surgery between 1998 and 2013 were retrospectively reviewed and analyzed. Results: In 28 (61%) patients with T4 tumors, extended procedures (more than rib resection) were performed. There were 37 (80%) lobectomies, 6 (13%) pneumonectomies, and 3 (7%) sublobar resections. A total of 44 (96%) patients had R0 resection. About 30-day mortality was 0%, major surgical complications occurred in 9 (19.6%) patients. Overall survival (OS) at 5-years was 63%. Disease-free survival (DFS) at 5-years was 45%. At multivariate cox regression analysis adjusted for clinical factors, T factor (T3/T4) and extended surgical procedures did not impact survival. However, pathological positive N stage had a negative impact on OS and lack of pathological response negatively impacted both OS and DFS. Conclusion: Trimodality treatment including radical resection for Pancoast tumors provides good surgical outcome and favorable long-term results. Survival of patients with T4 tumors and extended surgical procedures comparable to that of patients with T3 tumors undergoing rib resection only.

Original languageEnglish
Pages (from-to)227-235
Number of pages9
JournalJournal of Surgical Oncology
Volume116
Issue number2
DOIs
Publication statusPublished - Aug 1 2017

    Fingerprint

Keywords

  • chemoradiation therapy
  • non-small cell lung cancer
  • pancoast tumor
  • trimodality therapy

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Waseda, R., Klikovits, T., Hoda, M. A., Hoetzenecker, K., Bertoglio, P., Dieckmann, K., Zöchbauer-Müller, S., Pirker, R., Prosch, H., Döme, B., & Klepetko, W. (2017). Trimodality therapy for Pancoast tumors: T4 is not a contraindication to radical surgery. Journal of Surgical Oncology, 116(2), 227-235. https://doi.org/10.1002/jso.24629